245 related articles for article (PubMed ID: 30022385)
41. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
42. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
Ono A; Kenmotsu H; Watanabe M; Serizawa M; Mori K; Imai H; Taira T; Naito T; Murakami H; Nakajima T; Ohde Y; Endo M; Yamamoto N; Koh Y; Takahashi T
Ann Oncol; 2014 Oct; 25(10):1948-1953. PubMed ID: 25009007
[TBL] [Abstract][Full Text] [Related]
43. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
Okamoto T; Kitahara H; Shimamatsu S; Katsura M; Takada K; Fujishita T; Suzuki Y; Morodomi Y; Tagawa T; Maehara Y
Anticancer Res; 2016 Jun; 36(6):3057-63. PubMed ID: 27272827
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
46. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma.
Tseng JS; Wang CL; Yang TY; Chen CY; Yang CT; Chen KC; Hsu KH; Tsai CR; Chang GC
Lung Cancer; 2015 Dec; 90(3):472-6. PubMed ID: 26474957
[TBL] [Abstract][Full Text] [Related]
47. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
48. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
49. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.
Ohba T; Toyokawa G; Kometani T; Nosaki K; Hirai F; Yamaguchi M; Hamatake M; Seto T; Ichinose Y; Sugio K
Surg Today; 2014 Mar; 44(3):478-86. PubMed ID: 23609009
[TBL] [Abstract][Full Text] [Related]
50. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Wang Y; Li RQ; Ai YQ; Zhang J; Zhao PZ; Li YF; He WJ; Xia YX; Li WH
Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
[TBL] [Abstract][Full Text] [Related]
51. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
52. [The efficacy and influence factors analysis of EGFR TKIs on patients with lung adenosquamous carcinoma].
Zhou SY; Hu XS; Li JL; Wang Y; Liu YT; Xing PY; Yang JL; Lin H; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):776-781. PubMed ID: 30392343
[No Abstract] [Full Text] [Related]
53. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
54. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
Sakashita S; Shiba-Ishii A; Murata Y; Sekimoto R; Minami Y; Sato Y; Noguchi M
Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
Kaseda K; Asakura K; Kazama A; Ozawa Y
Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
[TBL] [Abstract][Full Text] [Related]
56. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Jain A; Lim C; Gan EM; Ng DZ; Ng QS; Ang MK; Takano A; Chan KS; Tan WM; Kanesvaran R; Toh CK; Loo CM; Hsu AA; Devanand A; Lim CH; Koong HN; Koh T; Fong KW; Yap SP; Kim SW; Chowbay B; Oon L; Lim KH; Lim WT; Tan EH; Tan DS
PLoS One; 2015; 10(5):e0123587. PubMed ID: 25955322
[TBL] [Abstract][Full Text] [Related]
57. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.
Li M; Li C; Ke L; Zhan M; Cheng M
Oncol Lett; 2018 Dec; 16(6):7057-7067. PubMed ID: 30546439
[TBL] [Abstract][Full Text] [Related]
58. Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China.
Li H; Cao J; Zhang X; Song X; Wang W; Jia S; Li Z; Jia H; Cao X; Zhou W; Lian J; Han S; Yang W; Xi Y; Lian S; Jing H
Clin Exp Metastasis; 2017 Jan; 34(1):63-71. PubMed ID: 27888377
[TBL] [Abstract][Full Text] [Related]
59. Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.
Paliogiannis P; Colombino M; Sini MC; Manca A; Casula M; Palomba G; Pisano M; Doneddu V; Zinellu A; Santeufemia D; ; Sotgiu G; Cossu A; Palmieri G
BMC Pulm Med; 2022 Jan; 22(1):32. PubMed ID: 35012520
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.
She Y; Li S; Deng J; Ren Y; Zhao M; Zhong Y; He Y; Chen Q; Zhao D; Zhu Y; Hou L; Wu C; Xie D; Chen C
Eur J Cancer; 2022 Dec; 177():53-62. PubMed ID: 36323053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
